24/7 Market News Snapshot 24 February, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)

February 24, 2025

DENVER, Colo., 24 February, 2025 (247marketnews.com) – (NASDAQ:PEPG) are discussed in this article.
PepGen Inc. has emerged as a focal point in the biotechnology sector, with its stock experiencing a noteworthy increase, reaching $2.026 in pre-market trading, a surge of 47.88% from the previous close of $1.370. This rise is accompanied by a substantial trading volume of 2.68 million shares, reflecting heightened investor interest and optimism surrounding the company’s innovative developments.

The company is at the forefront of pioneering oligonucleotide therapies, specifically targeting severe neuromuscular and neurological disorders. In a significant announcement, PepGen shared promising initial findings from its FREEDOM-DM1 study, which evaluates its investigational therapy, PGN-EDODM1, for treating myotonic dystrophy type 1 (DM1). The trial results highlight notable splicing correction in patients following a single dose, underscoring the effectiveness of PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform that enhances therapeutic engagement at the targeted cellular sites.

Dr. James McArthur, President and CEO of PepGen, emphasized the significance of these early results, stating, “The initial results from FREEDOM-DM1 demonstrate encouraging efficacy and an emerging safety profile. We remain steadfast in our dedication to delivering transformative treatments for neuromuscular disorders, addressing the root causes of these diseases to enhance patient outcomes.” The company not only plans to advance the FREEDOM-DM1 findings but has also initiated the FREEDOM2 phase study while continuing the CONNECT1 and CONNECT2 trials for another investigational therapy aimed at Duchenne muscular dystrophy (DMD), despite a recent clinical hold from regulatory bodies in certain regions.

PepGen’s financial standing remains robust, with cash reserves reported at $120.2 million as of December 31, 2024, sufficient to sustain operations until 2026. As the company continues its clinical development initiatives, it aims to provide further data releases throughout the year, marking significant milestones in its quest to revolutionize treatment options for patients confronting challenging neuromuscular diseases.

Related news for (PEPG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.